BridgeMD
New treatment option for Obstructive Hypertrophic Cardiomyopathy
Official title A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
ClinicalTrials.gov ID: NCT07021976
What this study is testing
What is HRS-1893 Tablets?
HRS-1893 Tablets is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for obstructive hypertrophic cardiomyopathy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Age 18-85 years old, gender unlimited.
- BMI\<35 kg/m2.
- The diagnosis was obstructive hypertrophic cardiomyopathy.
- Laboratory determination of echocardiography showed that Rest LVOT-G≥50 mmHg, or Rest LVOT-G≥30 mmHg and LVOT-G≥50 mmHg after Valsalva action.
- Echocardiographic laboratory tests showed LVEF≥60%.
You likely can't join if
- Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar...
- Had a history of severe valvular heart disease.
- Abnormal laboratory test results during screening, or any other clinically significant abnormal screening laboratory values, which are determined by...
- Other circumstances where the researchers consider the people unsuitable to participate in this trial, such as physical or mental illnesses or...
See the full eligibility criteria
- Age 18-85 years old, gender unlimited.
- BMI\<35 kg/m2.
- The diagnosis was obstructive hypertrophic cardiomyopathy.
- Laboratory determination of echocardiography showed that Rest LVOT-G≥50 mmHg, or Rest LVOT-G≥30 mmHg and LVOT-G≥50 mmHg after Valsalva action.
- Echocardiographic laboratory tests showed LVEF≥60%.
- NYHA classification: Grade II - III.
- Understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study.
- Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM).
- Had a history of severe valvular heart disease.
- Abnormal laboratory test results during screening, or any other clinically significant abnormal screening laboratory values, which are determined by the researcher to be unsuitable for inclusion.
- Other circumstances where the researchers consider the people unsuitable to participate in this trial, such as physical or mental illnesses or conditions that may increase the risk of the trial, affect the people'...
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.